Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.43 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16399740 | 0.78 | ELANE (0.44) | ELANECTSGPRTN3AMPD2ALDH1A1 | |
| SCHEMBL16401375 | 0.77 | ELANE (0.43) | ELANECTSGPRTN3AMPD2ALDH1A1 | |
| SCHEMBL16400524 | 0.76 | ELANE (0.44) | ELANECTSGPRTN3AMPD2ALDH1A1 | |
| SCHEMBL16400527 | 0.73 | GAA (0.40) | ELANECTSGPRTN3AMPD2ALDH1A1 | |
| SCHEMBL16399111 | 0.73 | AMPD2 (0.43) | ELANECTSGPRTN3AMPD2ALDH1A1 | |
| SCHEMBL16400060 | 0.70 | ELANE (0.42) | ELANECTSGPRTN3ALDH1A1GAA | |
| SCHEMBL17685971 | 0.69 | ELANE (0.38) | ELANECTSGPRTN3AMPD2ALDH1A1 | |
| SCHEMBL16399447 | 0.68 | AMPD2 (0.44) | ELANECTSGPRTN3AMPD2ALDH1A1 | |
| SCHEMBL16400240 | 0.67 | ELANE (0.43) | ELANECTSGPRTN3AMPD2ALDH1A1 | |
| SCHEMBL17055358 | 0.66 | KMT2A (0.53) | ELANECTSGPRTN3GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-3004086-A1 | SUBSTITUTED BENZOXAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195230-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | ELANE 447/4885CTSG 2955/4885PRTN3 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.